CA2308765A1 - Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation - Google Patents

Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation Download PDF

Info

Publication number
CA2308765A1
CA2308765A1 CA002308765A CA2308765A CA2308765A1 CA 2308765 A1 CA2308765 A1 CA 2308765A1 CA 002308765 A CA002308765 A CA 002308765A CA 2308765 A CA2308765 A CA 2308765A CA 2308765 A1 CA2308765 A1 CA 2308765A1
Authority
CA
Canada
Prior art keywords
protein
nucleic acid
acid sequence
effective amount
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002308765A
Other languages
English (en)
Other versions
CA2308765C (fr
Inventor
Reginald M. Gorczynski
David A. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22058127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2308765(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2308765A1 publication Critical patent/CA2308765A1/fr
Application granted granted Critical
Publication of CA2308765C publication Critical patent/CA2308765C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Cette invention concerne des procédés et des compositions permettant d'induire une immunodépression. Ces procédés consistent à administrer une dose efficace de protéine OX-2 ou un acide nucléique codant pour une protéine OX-2. Ils conviennent particulièrement pour prévenir les rejets de greffes, les pertes fotales ainsi que les maladies auto-immunes et les allergies. L'invention porte également sur des techniques et des compositions permettant d'éviter une immunosuppression. Ces procédés comportent l'administration d'une dose efficace d'un agent inhibant la protéine OX-2.
CA2308765A 1997-11-07 1998-11-06 Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation Expired - Fee Related CA2308765C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6476497P 1997-11-07 1997-11-07
US60/064,764 1997-11-07
PCT/CA1998/001038 WO1999024565A1 (fr) 1997-11-07 1998-11-06 Procedes et compositions pour immunomodulation

Publications (2)

Publication Number Publication Date
CA2308765A1 true CA2308765A1 (fr) 1999-05-20
CA2308765C CA2308765C (fr) 2010-10-12

Family

ID=22058127

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2308765A Expired - Fee Related CA2308765C (fr) 1997-11-07 1998-11-06 Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation

Country Status (12)

Country Link
US (6) US6338851B1 (fr)
EP (1) EP1032662B1 (fr)
JP (2) JP4584447B2 (fr)
AT (1) ATE319825T1 (fr)
AU (1) AU748587B2 (fr)
CA (1) CA2308765C (fr)
CY (1) CY1105364T1 (fr)
DE (1) DE69833779T2 (fr)
DK (1) DK1032662T3 (fr)
ES (1) ES2260852T3 (fr)
PT (1) PT1032662E (fr)
WO (1) WO1999024565A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
EP1032662B1 (fr) 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Procedes et compositions pour immunomodulation
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
AU4341300A (en) * 1999-04-13 2000-11-14 Schering Corporation Novel uses of mammalian ox2 protein and related reagents
AU6615500A (en) * 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
WO2001068697A2 (fr) * 2000-03-17 2001-09-20 Gorczynski Reginald M Techniques et compositions relatifs à l'immunorégulation
ATE372130T1 (de) * 2000-04-22 2007-09-15 Pharmedartis Gmbh Apoptotika
CA2417874C (fr) * 2000-08-03 2012-10-02 Transplantation Technologies Inc. Utilisation des inhibiteurs ox-2 pour le traitement du cancer
AUPR069500A0 (en) * 2000-10-11 2000-11-09 Coster, Douglas John Tissue modification
ATE406385T1 (de) 2000-11-22 2008-09-15 Trillium Therapeutics Inc Verkürztes cd200
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CA2436595C (fr) 2000-12-08 2011-11-08 Alexion Pharmaceuticals, Inc. Lignee cellulaire de la leucemie lymphoide chronique et son utilisation pour la production d'un anticorps
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6906237B2 (en) * 2001-02-27 2005-06-14 G. Scott Herron Vivo assay for anti angiogenic compounds
IL160229A0 (en) 2001-08-10 2004-07-25 Genset Sa Polynucleotides, polypeptides encoded thereby and their use
CA2462883A1 (fr) * 2001-10-12 2003-04-17 Schering Corporation Utilisation d'anticorps bispecifiques pour reguler des reponses immunitaires
US7196243B2 (en) 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
AU2003299823A1 (en) * 2002-12-27 2004-07-29 Schering Corporation Methods of inducing and maintaining immune tolerance
EP2604703B1 (fr) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Procédés permettant d'évaluer la survie d'un greffon chez un destinataire d'une transplantation d'organe solide
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
GB0506721D0 (en) * 2005-04-01 2005-05-11 Univ Glasgow Soluble immunoregulatory factor
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
US20100178652A1 (en) * 2007-01-05 2010-07-15 Litherland Sally A Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease
WO2009014745A1 (fr) 2007-07-25 2009-01-29 Alexion Pharmaceuticals, Inc. Anticorps dirigés contre cd200 et leurs utilisations dans l'inhibition de réponses immunitaires
AU2008279618B2 (en) 2007-07-25 2014-05-22 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
ES2492498T3 (es) 2009-01-15 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
EP2507630B1 (fr) 2009-12-02 2017-01-25 The Board of Trustees of The Leland Stanford Junior University Biomarqueurs pour déterminer un xénotype tolérant à l'allogreffe
SG182408A1 (en) 2010-01-11 2012-08-30 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
KR20130036192A (ko) 2010-02-11 2013-04-11 알렉시온 파마슈티칼스, 인코포레이티드 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
WO2011119980A1 (fr) 2010-03-25 2011-09-29 The Board Of Trustees Of The Leland Stanford Junior University Biomarqueurs protéiques et génétiques pour le rejet de greffes d'organes
RU2601154C2 (ru) 2011-03-11 2016-10-27 Синаджива Байофарма Корп Гибридные белки npp1
EP2723380B1 (fr) 2011-06-24 2019-08-21 Stephen D. Gillies Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
EP3967755B1 (fr) 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Npp1 soluble pour une utilisation dans une méthode de traitement du pseudoxanthome élastique
AU2016349897B2 (en) 2015-11-03 2021-11-04 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
EP3471747A1 (fr) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Méthodes de traitement d'une prolifération myo-intimale
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
WO2019084682A1 (fr) 2017-10-30 2019-05-09 Mcmaster University Méthodes pour le diagnostic et le traitement de l'endométriose
WO2019126133A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Formulations liquides d'anticorps anti-cd200
WO2019126536A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Anticorps humanisés anti-cd200 et leurs utilisations
WO2020150149A1 (fr) 2019-01-14 2020-07-23 Regents Of The University Of Minnesota Ligands cd200ar pour immunothérapie anticancéreuse
GB202303291D0 (en) * 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580812A1 (fr) * 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Recepteur ctla, proteines hybrides qui le contiennent et ses applications
GB9505653D0 (en) * 1995-03-21 1995-05-10 Shober Wharton Method of pest control
AU1144097A (en) * 1995-12-08 1997-07-03 Brigham And Women's Hospital Ox-2 costimulatory molecule
EP0892643B2 (fr) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1032662B1 (fr) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Procedes et compositions pour immunomodulation
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
WO2001068697A2 (fr) 2000-03-17 2001-09-20 Gorczynski Reginald M Techniques et compositions relatifs à l'immunorégulation
ATE406385T1 (de) 2000-11-22 2008-09-15 Trillium Therapeutics Inc Verkürztes cd200
CA2448668A1 (fr) 2001-05-24 2002-11-28 Trillium Therapeutics Inc. Modulation des recepteurs de cd200
US7196243B2 (en) * 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery

Also Published As

Publication number Publication date
HK1030625A1 (en) 2001-05-11
US6338851B1 (en) 2002-01-15
WO1999024565A1 (fr) 1999-05-20
US20020151485A1 (en) 2002-10-17
DK1032662T3 (da) 2006-07-03
ES2260852T3 (es) 2006-11-01
JP4584447B2 (ja) 2010-11-24
DE69833779T2 (de) 2006-11-30
US6984625B2 (en) 2006-01-10
PT1032662E (pt) 2006-07-31
US20020086011A1 (en) 2002-07-04
CY1105364T1 (el) 2010-03-03
US20110206668A1 (en) 2011-08-25
EP1032662A1 (fr) 2000-09-06
JP2010155846A (ja) 2010-07-15
ATE319825T1 (de) 2006-03-15
AU748587B2 (en) 2002-06-06
AU1017399A (en) 1999-05-31
EP1032662B1 (fr) 2006-03-08
DE69833779D1 (de) 2006-05-04
JP2001522867A (ja) 2001-11-20
US7902151B2 (en) 2011-03-08
CA2308765C (fr) 2010-10-12
US20090232825A1 (en) 2009-09-17
US6652858B2 (en) 2003-11-25
US6749854B2 (en) 2004-06-15
US20020103151A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
CA2308765A1 (fr) Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation
D'Alessio et al. Seminal RNase: a unique member of the ribonuclease superfamily
CA2102208A1 (fr) Domaines de liaison dans les proteines notch et delta
CA2242542A1 (fr) Compositions et methodes a usage therapeutique
IL161591A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU3847997A (en) Inhibitors of the interaction between P53 and MDM2
WO1999027109A3 (fr) PROTEINES LIANT LA MATRICE EXTRACELLULAIRE ISSUES DU $i(STAPHILOCOCCUS AUREUS)
WO1998033509A3 (fr) Proprietes utiles de la lactoferrine humaine et de variants de celle-ci
GB2268492B (en) Protein based delivery system
EP1741779A3 (fr) Inhibition du facteur inhibiteur de la migration dans le traitement des maladies impliquant une toxicité liée aux cytokines
WO1994016073A3 (fr) Procedes et reactifs permettant l'inhibition de la furine endoprotease
CA2096654A1 (fr) Extraction des anticorps de derives sanguins tout en conservant les facteurs de coagulation
EP3708182A1 (fr) Compositions et méthodes pour préparer un sujet à l'implantation d'un organe ou d'un non-organe
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
CA2417874A1 (fr) Utilisation des inhibiteurs ox-2 pour le traitement du cancer
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
US20080125390A1 (en) Methods for Modulating Immune and Inflammatory Responses
GB8900812D0 (en) Pharmaceutical method and compositions
EP1005324A4 (fr) Compositions diffusant des agents biologiques et leurs procedes de preparation
WO2002058589A3 (fr) Agents et methodes favorisant la croissance osseuse
WO2001040302A3 (fr) Rejet d'organe transplante et etats pathologiques associes
CA2327353A1 (fr) Proteines de structure du virus de la maladie affectant le pancreas des poissons et utilisations de ces dernieres
EP1211311A3 (fr) Lymphocytes activés issus du sang de cordon ombilical et compositions contenant ces lymphocytes
WO2003054019A3 (fr) Anticorps anti-tirc7 therapeutiques destines a etre utilises dans les maladies immunes ou autres
WO2001094586A3 (fr) Anticorps non agonistiques diriges contre gp 39 humaine, compositions les contenant et leur utilisation therapeutique

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141106